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Abstract
Background: Adherence problems with coitally dependent, female-initiated HIV prevention methods have
contributed to several trials’ failure to establish efficacy. Continuous use of a cervical barrier with once-daily
cleaning and immediate reinsertion may simplify use for women and improve adherence. We assessed the
acceptability and safety of precoital and continuous use of the Duet®, a cervical barrier and gel delivery system, in
Zimbabwean women.
Methods: Using a two-arm crossover design with a parallel observation group, we randomized 103 women in a
2:2:1 ratio: (1) to use the Duet continuously for 14 days, followed by a minimum of seven days of washout and
then 14 days of precoital use; (2) to use the same Duet regimens in reverse order; or (3) for observation only.
Women were aged 18 to 40 years; half were recruited from a pool of previous diaphragm study participants and
the other half from the general community. Acceptability and adherence were assessed through an interviewer-
administered questionnaire at each of two follow-up visits. Safety was monitored through pelvic speculum exams
and report of adverse events.
Results: The proportion of women who reported consistent Duet use during sex was virtually identical during
continuous and precoital regimens (88.6% vs. 88.9%). Partner refusal was the most common reason cited for non-
use during sex in both use regimens. Not having the device handy was the most common reason cited for non-
daily use (in the continuous regimen). Most women were “very comfortable” using it continuously (86.3%) and
inserting it precoitally (92.8%). The most favoured Duet attribute was that it did not interfere with “natural” sex
(55%). The least favoured Duet attribute was the concern that it might come out during sex (71.3%). No serious
adverse events were reported during the study; 57 participants reported 90 adverse events classified as mild or
moderate. There were no statistically significant differences in: (1) the proportion of women reporting adverse
events; (2) the severity of events among those using the Duet and observational controls; or (3) event severity
reported during each regimen use period.
Conclusions: In this study, the Duet was found to be acceptable and safe when inserted precoitally or used
continuously for 14 days. Assignment to use of the Duet continuously did not increase adherence to the Duet
during sex. Future HIV prevention trials should evaluate use of the Duet (precoitally and continuously) with
promising microbicide candidates.
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Female-initiated methods to prevent HIV, including
microbicides, intravaginal rings and cervical barriers, are
currently being investigated in clinical trials to address
the disproportionate burden of HIV in women, particu-
larly in the highest prevalence regions, such as sub-
Saharan Africa [1]. Such technologies would provide
additional disease prevention options to women and
couples, and might be particularly beneficial in partner-
ships where male condom use is not feasible.
Thus far, 11 trials of microbicide candidates and one
trial of the diaphragm with a lubricant gel were unable
to detect a significant reduction in HIV acquisition in
w o m e n[ 2 ] .O n ei m p o r t a n tr e a s o nt h a tt r i a l so ft h e s e
investigational female-initiated products may have been
unable to detect a significant protective effect is the
lower-than-anticipated adherence levels reported by trial
participants, which may have diluted the power to mea-
sure the effectiveness of the intervention had there been
true biological efficacy [2-4]. Unlike male circumcision,
these interventions are user dependent, and optimal
adherence necessitates the insertion of a device and/or
applicator of gel shortly before sex, which may be diffi-
cult for practical, cultural or other reasons.
One potential strategy to simplify use and increase
adherence to female-initiated methods is to make them
coitally independent. Continuous use of cervical barriers
has been promoted as such a strategy: products are
always worn and only removed once daily for cleaning,
and then immediately reinserted. There are limited data
on the safety and acceptability of this approach. Two
pilot studies in Madagascar promoted continuous use of
the diaphragm for four or eight weeks among sex work-
ers. In one study, 92% of respondents reported being
somewhat comfortable or comfortable with this techni-
que, although at 20% of visits, the participants reported
multiple daily insertions of the diaphragm, indicating
that the continuous-use protocol was not followed [5].
In the other study, 88% of women reported continuous
diaphragm use in the previous day at Week 1, and this
usage increased to 93% by Week 8 [6]. Although pri-
marily focused on the acceptability and feasibility of
continuous use of the diaphragm among the study
populations, these studies also monitored safety out-
comes and reported that continuous use appeared safe
[5,6].
In this study, we aimed primarily to assess the accept-
ability of the Duet® cervical barrier (with single-use 10 g
BufferGel sachets) when inserted precoitally or used
continuously in an African population, and to simulta-
neously monitor safety using a parallel observation
group. The Duet is a diaphragm-like device designed by
ReProtect, Inc. (Baltimore, MD, USA) to act as both a
cervical barrier and a gel delivery system capable of deli-
vering gel on both its cervical and vaginal lumen sides.
Its single-size design is intended to fit most women and
does not require medical fitting. It was originally
designed for use with BufferGel®, an acid-buffering gel
that has been shown to have microbicidal activity
in vitro and in animal models [7-9], and to be safe for
human use and effective in preventing pregnancy when
used with a diaphragm, although ineffective on its own
in preventing HIV [10-13]. The functional performance,
safety and acceptability of the Duet (prefilled with Buf-
ferGel) was first investigated in the United States and
the Dominican Republic among 30 couples who used
the device during sex twice in one week [14]. In that
study, the Duet was found to be safe and acceptable,
and it was concluded that further research into the pro-
duct as a potential disease prevention method was war-
ranted [14].
Importantly, the Duet can be used with other vaginal
gels, including alternative microbicide candidates, and a
combination product could theoretically provide
enhanced protection against diseases through the addi-
tive effect of a physical barrier and gel. The results from
this study are important to consider within this context.
Methods
Study setting and population
The study was conducted from December 2008 to May
2009 at a research site in Epworth, a peri-urban town-
ship within the municipal district of Harare, the capital
city of Zimbabwe. Inclusion criteria included: being 18
to 40 years of age; being sexually active (one or more
acts of vaginal sex per week for the three months prior
to enrolment); being non-pregnant and on a highly
effective form of contraception; having no genital
abnormalities or symptoms; being able to successfully
insert and remove the Duet within three attempts; and
being willing and able to provide informed consent.
Women with abnormal menstrual cycles were excluded.
HIV-positive status was not an exclusion criterion, but
women had to be physically healthy in the judgment of
the study clinicians, with no history of any serious
acute, chronic or progressive disease, and no known
allergy to latex. As a secondary objective, the study
aimed to evaluate how previous diaphragm experience
might impact the acceptability of the Duet worn con-
tinuously and precoitally. Thus, half of the enrolled
study sample participants were purposively recruited
from a randomly selected list of former intervention-
arm participants in the Methods for Improving Repro-
ductive Health in Africa (MIRA) trial (a Phase III trial
of the effectiveness of the diaphragm in preventing
HIV), who lived in the Epworth area and were within
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for this study were not former MIRA participants and
were either recruited by the study outreach worker at
community venues or walked in to the research centre.
Study design
The study was an open-label, two-arm crossover study
with a parallel observation group randomized in a 2:2:1
ratio (see Figure 1). Forty percent of women (the conti-
nuous!precoital group) were randomized to wear the
Duet continuously for 14 days, followed by a minimum
of seven days of washout, and 14 days of precoital use;
40% of women were randomized to the reverse-order
regimen (the precoital!continuous group). To better
inform the safety evaluation, the remaining 20% were
assigned to an observation-only arm. Duet-use regimens
and study visits were scheduled to avoid menses. All
groups received male condoms, and safe sex and risk
reduction counselling.
Study products
The Duet is similar in structure to a diaphragm, but
with a hard rim and dome. However, the Duet has a
wider rim and a reservoir surrounding the rim at the
base of the dome that acts as a gel collection area (see
Figure 2). BufferGel was provided in single-use 10 g
sachets (similar to condiment packaging). Gel was
applied on both the vaginal and cervical sides of the
Duet prior to insertion. Prior research has been con-
ducted on the acceptability of the Duet as a menstrual
collection device [16], and contraceptive efficacy studies
are planned. However, participants were advised that
this study was investigating the product’s potential use
for delivery of gels for HIV and sexually transmitted
infection prevention.
Study procedures
At screening, participants gave oral consent to complete
a short, interviewer-administered eligibility question-
naire, and participants who met initial inclusion and
exclusion criteria were then asked to provide written
informed consent for study procedures. A urine speci-
men was collected for pregnancy testing, and partici-
pants were interviewed about their demographic and
clinical history. Non-pregnant participants were given a
pelvic speculum exam to rule out genital abnormalities,
signs or symptoms, and two swabs were collected from
the vaginal fornices for assessment of bacterial vaginosis
(BV). One was used for a rapid point-of-care assay
(BVBlue®, Gryphus Diagnostics, Knoxville, TN, USA),
and the second for assessment of BV using both
Amsell’s criteria and Nugent scoring [17,18].
BV and all other genital signs and symptoms were
treated syndromically, according to Zimbabwe National
Syndromic Management guidelines [19]. Clinicians
demonstrated how to load gel in and on the Duet from
the sachet, and inserted it in a translucent pelvic model.
Participants then practiced the insertion and removal of
the Duet on themselves. All potential participants were
able to successfully insert and remove the Duet within
three attempts.
The randomization scheme was based on a permuted
block design with randomized blocks of sizes 5 and 10.
Participants randomized to the continuous!precoital
group initiated the continuous-use regimen immediately
and inserted the Duet while in the clinic. They were
given 14 sachets of gel, the Duet plastic case, condoms,
and an illustrated, local language (Shona) or English
Duet instruction sheet for continuous use.
Participants in the precoital!continuous group were
given a Duet to insert within one hour prior to sex, as
Figure 1 Study profile.
Figure 2 Diagram of Duet and method for gel application.
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reported coital frequency, male condoms, a Duet plastic
case, and illustrated instruction sheet for precoital use.
Precoital use specified that the Duet should be inserted
within one hour prior to sex, and removed no sooner
than one hour and no later than 24 hours postcoitus.
All participants were given male condoms.
Participants in the Duet-use groups were also pro-
vided with panty liners in case of gel leakage, and a bar
of mild soap to clean the Duet. Following randomiza-
tion, participants completed an interviewer-administered
baseline acceptability and adherence questionnaire,
received safe sex and risk reduction counselling, and
were scheduled for their first follow-up visit 14 days
after enrolment (a window of about seven days was
allowable). Participants were encouraged to come to the
clinic at any time if they required clinical attention,
counselling or resupply of gel or condoms.
At the first follow up, participants completed an inter-
viewer-administered adherence questionnaire. Next, a
clinician conducted a clinical interview and pelvic spec-
ulum exam to identify any adverse events (AEs), and to
obtain vaginal swabs for BV diagnosis. Women with
genital signs or symptoms of infection were treated syn-
dromically, as described, and scheduled to return to the
clinic within seven to 14 days for evaluation. Partici-
pants in the Duet-use groups received crossover coun-
selling to review the procedures and dates for switching
their use regimen following menses and washout. Used
and unused gel sachets were returned and inventoried,
and new gel sachets and instructions were issued in
accordance with the subsequent-use regimen.
All participants received condoms and risk reduction
counselling, and completed an interviewer-administered
acceptability questionnaire. After reviewing locator
information, participants were reimbursed for their
transport and time, and scheduled to return to the clinic
approximately one month later. A study outreach
worker contacted Duet-use participants at home within
two days of the target date for crossing over to the new
Duet-use regimen to ensure that change in regimen
occurred correctly.
The second and final follow-up visit followed the same
sequence of procedures as the first follow up, except for
crossover counselling. All study products (Duet, used
and unused gel sachets) were permanently collected and
inventoried, and participants were discontinued from
the clinical portion of the study. Updated locator infor-
mation and willingness to be contacted within 60 days
to participate in a qualitative component of the study
(data to be presented in a separate paper) were solicited
from intervention group women.
Measures and statistical analysis
We assessed the acceptability, adherence and safety of
the Duet for use among African women when used con-
tinuously for 14 days or inserted precoitally for 14 days.
Acceptability measures
Among intervention group women, the comfort of wear-
ing the Duet during each regimen was assessed at the
visit immediately following that regimen. At the accept-
ability assessment at the final visit, the following infor-
mation was obtained: measures that assessed willingness
to use the Duet if one perceived oneself to be at risk for
HIV; comfort using the gel sachets and loading gel in
the device; preferences for the continuous versus precoi-
tal regimen for the participant and her perception of her
partner’s preference; and the characteristics most
women found favourable and unfavourable about Duet
use for themselves and their partners (i.e., the appear-
ance of the Duet and the effect on sex). After we deter-
mined that no differences were observed in acceptability
measures by the Duet group assignment (i.e., order-
effect), we combined acceptability results for both Duet-
use groups.
Adherence measures
We computed the mean, median and range for the
number of days the Duet was reported to be used dur-
ing the continuous-use regimen, and the number of sex
acts during both regimens. We evaluated adherence to
the assigned regimen by computing the proportion of
days (100%, ≥ 80%) that the Duet was worn during the
continuous-use regimen and the proportion of sex acts
(100%, ≥ 80%) during which the Duet was worn during
both the continuous-use and precoital-use regimens.
Condom use adherence and the number of times the
Duet came out on its own were tabulated. We also
assessed the reasons for sub-optimal adherence among
those who were imperfect users. Finally, to explore the
potential influence of previous cervical barrier use on
adherence and acceptability to the Duet, we used chi-
square statistics to compare the proportion of women
reporting key measures by prior diaphragm experience.
Safety measures
These were based on a tabulation of participants’ self-
reports of AEs and clinician classification of those
events, abnormal physical findings, the results of the
point-of-care BV test (Amsell’s criteria and Nugent
score not shown), and reports of emotional problems or
social harms. For AEs, we computed the number of
individuals experiencing events, the number of events
observed, and the number of events per 100 person
w e e k so fo b s e r v a t i o n ,b yg r o u p .T h i ss t u d yw a sn o t
powered to identify statistical differences between
groups. However, for illustrative purposes, we compared:
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those using the Duet versus observational controls using
Fisher’s exact test statistics; and (2) the proportion of
women reporting AEs during the continuous-use versus
precoital-use regimens. Because participants participated
in each regimen, the data were treated as paired data
and analyzed using a McNemar’s test.
The study was carried out under the principles out-
lined in the Declaration of Helsinki and was reviewed
and approved by Institutional Review Boards at RTI
International (USA) and the Medical Research Council
of Zimbabwe. The Medicines Control Authority of Zim-
babwe provided regulatory approval for the conduct of
the study.
Results
Study sample
Table 1 presents the baseline characteristics of the 103
women enrolled in the study (42 continuous!precoital
group, 41 precoital!continuous group, 20 observa-
tion-only group), who had a mean and median age of
30 years, were all married, and mostly Shona (66%),
the majority tribal group in Zimbabwe. All women had
at least one child, and the majority (63%) had more
than two children. Use of a highly effective contracep-
tive was an inclusion criterion; most women (66.7%)
were using oral contraceptives, while 28.4% were using
injectables.
For sexual risk behavior, the mean and median num-
ber of sexual partners in the past three months was one,
and less than 15% had ever been treated for a sexually
transmitted infection (STI), although 14% also reported
having some vaginal symptoms in the past three months
and almost one-fifth (19.2%) were BV positive per rapid
assay (and asymptomatic, thus not treated). While 81%
reported having ever used male condoms in their life-
time, only half (51.2%) reported using male condoms in
the past three months.
Twelve of the 52 former MIRA participants (23.1%)
had used a diaphragm in the past three months, but
none of these women cited the diaphragm as a current
contraceptive method. Randomization groups were lar-
gely similar for all measured baseline characteristics;
although the parity distribution for women in the conti-
nuous!precoital group was lower than those in the
other two groups, these women were also more likely to
be BV positive (per rapid assay) at baseline. Women in
the observation group were slightly more likely to report
ever having used male condoms. All enrolled partici-
pants were able to wear the Duet device; only two of
the 135 women screened were unable to wear the Duet
due to an unsuitable fit (see Figure 1).
Adherence to Duet-use regimen
We examined adherence among Duet users by regimen.
When participants were assigned to use the Duet con-
tinuously, they wore it all day or at least part of the day
for, on average, 13.3 of the target 14 days (median 14,
range 7-14; see Table 2). Overall, the majority (81%) of
women reported that they wore the Duet for all of their
continuous-use days, and 90% used it for at least 80% of
the days they were instructed to use it (see Table 2).
During the continuous-use regimen, each woman
reported an average of 10 sex acts overall (mean 10.2,
median 10) for the 14-day period, and 88.6% reported
using the Duet every time they had sex, while 63.3%
reported using condoms every time.
During their precoital regimen, women reported a
similar number of sex acts for the 14-day period (mean
10.5, median 10), and the overall proportion of women
who reported consistent Duet use during sex was vir-
tually identical to that during the continuous-use regi-
men (88.9%). Reported condom use during sex was
similar to the continuous-use regimen, with roughly
two-thirds of women reporting condom use for 100% of
sex acts. Reports of crossover contamination and invo-
luntary Duet removal were rare (see Table 2). Compared
to those in the Duet groups, more women in the obser-
vation group (80%) reported consistent male condom
use, and they had only slightly fewer sex acts (mean 9.3,
median 8.5) during the 14-day periods assessed.
During both regimen periods, we asked women their
main reasons for not using the Duet every day or during
every act of sex, and supplied some categorical
responses, as well as an open-ended response. Although
the majority (range 79%-90%; see Table 2) indicated that
they had used it every time, partner refusal was the
most commonly cited reason for non-adherence during
sex in both regimen periods. Reasons for not using the
Duet every day during the continuous regimen were
more varied: the most common reason participants
cited was that they did not have it with them. Partner
refusal, discomfort, having menses, and non-use because
they did not have sex (demonstrating protocol misun-
derstanding) were also mentioned (see Table 2).
Acceptability
Overall, 86.3% of women reported feeling “very comfor-
table” wearing the Duet continuously for 14 days, while
92.8% reported the same for the precoital regimen (see
Table 3). Just over half (51.4%) of the participants
reported a preference for the precoital regimen, 10% felt
they were equivalent, and 39% preferred continuous use.
Women’s perceptions of their partner’s preferences for
continuous or precoital use mirrored their own
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they would “definitely” use the Duet if they thought they
were at risk for HIV and it could help protect them (see
Table 3).
Women were provided with a list of Duet attributes,
and asked to indicate which they found the most and
least favourable (see Table 3). The top three attributes
of the Duet that most participants cited were that it
doesn’ti n t e r f e r ew i t h“normal/natural sex” (55%), it is
reusable (18.8%), and it is inserted by the woman herself
(11.3%). Women ascribed their partner’s preferences to
the same three characteristics, although greater empha-
sis was placed on the first attribute: that it does not
interfere with “natural” sex.
The three least favourable characteristics of the Duet
for women were all hypothetical attributes: that it might
come out during sex (71.3%); and that it might change
the feeling of sex either for women themselves (13.8%)
or their partners (12.5%). Here again, women’s percep-
tions of their partners’ attitudes towards the least
favoured characteristics were similar to their own.
Women also reported that their partners would disfa-
v o u rt h eD u e ti ft h e yc o u l df e e li td u r i n gs e x ,a n dt h i s
ranked as potentially more disfavourable than a decrease
in the women’s own sexual pleasure.
Previous diaphragm experience
We compared responses to key adherence and accept-
ability measures between those who had previously used
ad i a p h r a g ma n dt h o s ew h oh a dn o t( “diaphragm
naïve”) using Fisher’s exact tests. No differences were
statistically significant; however, there was a trend
towards a preference for precoital use and better adher-
ence to the precoital-use regimen among diaphragm-
experienced women (see Table 4).
Safety
Adverse events
During the course of the study, no serious AEs
occurred; 57 participants reported 90 AEs that were
Table 1 Baseline characteristics of study sample, overall and by group assignment
Characteristic Total (n = 103) Continuous!precoital (n = 42) Precoital!continuous (n = 41) Observation (n = 20)
mean median mean median mean median mean median
Age 30.2 30.0 29.7 29.0 30.8 30.0 29.9 31.0
No. partners, past 3 mos. 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
n% n % n % n %
Ethnicity
Shona 67 65.7 28 66.7 27 65.9 12 63.2
Other 35 34.3 14 33.3 14 34.2 7 36.8
Relationship status
Married 102 100.0 42 100.0 41 100.0 19 100.0
Parity
1-2 39 38.2 22 52.4 13 31.7 4 21.0
3 or more 63 61.7 20 47.6 28 68.3 15 78.9
Current contraception
Long-term contraceptives 5 4.9 1 2.4 3 7.3 1 5.3
Injectables 29 28.4 12 28.6 14 34.2 3 15.8
Oral contraceptives 68 66.7 29 69.1 24 58.5 15 79.0
Ever treated for RTI/STI, lifetime
Yes 15 14.7 8 19.1 5 12.2 2 10.5
Any symptoms, past 3 mos.
Yes 14 13.7 6 14.3 6 14.6 2 10.5
BV status at baseline
Positive 19 19.2 12 28.6 4 10.8 3 15.0
Ever used male condoms
Yes 83 80.6 32 76.2 32 78.1 19 95.0
Male condom use, past 3 mos.
All of the time 8 9.5 1 3.0 4 12.5 3 15.8
Sometimes 35 41.7 16 48.5 9 28.1 10 52.6
Never 41 48.8 16 48.5 19 59.4 6 31.6
Ever used diaphragm, past 3 mos.
Yes 12 11.7 4 9.5 5 12.2 3 15.0
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no statistically significant differences in: (1) the propor-
tion of women reporting AEs (overall and reproductive
tract or urinary tract related); (2) the severity of events
reported among those using the Duet and those in the
observation group; or (3) the severity of events reported
during each regimen use period. Similarly, the distribu-
tion of relatedness to study product was not significant
(p >0.05) between the two Duet regimens (not applic-
able for observation group).
In total, 31 events (among 28 women) were classified
as related to study products: 13 “possibly”,1 0“prob-
ably”,e i g h t“probably not”,a n dz e r o“definitely” (see
Table 5). The majority of related events were reproduc-
tive tract or urinary tract related. However, a few parti-
cipants reported physiological/neurological discomfort
associated with the squatting position that some women
used for inserting and removing the Duet (i.e., numb-
ness or pain in hips).
Three individuals had abnormal physical exam find-
ings at each of two follow-up visits (data not shown).
One of these women had persistent cervical erythema
following her precoital-use regimen that necessitated
study discontinuation. The remaining five cases were
noted after the continuous-use regimen and included
findings of abnormal discharge (two women), candidiasis
(one), cervical ectopy (one) and suspected pelvic inflam-
matory disease (one). No epithelial disruptions were
identified.
The baseline distribution of BV-positive BV Blue
results was unevenly distributed by arm, with the conti-
nuous!precoital group having almost twice the propor-
tion as the other two groups (see Table 1). In the
follow-up period, across all groups, 19 BV Blue-positive
results were observed among 15 individuals (data not
shown). Seven of these 19 BV-positive results during fol-
low up were among women who were negative for BV
at enrolment, and this was distributed evenly as two
Table 2 Adherence to Duet use among intervention group participants (n = 83), by regimen
Continuous regimen (n = 80) Precoital regimen (n = 82)
Duet adherence mean med (range) mean med (range)
Days Duet worn 13.3 14.0 (7-14) NA NA
Number of sex acts 10.2 9.0 (2-42) 10.5 10.0 (2-42)
n%n %
Duet regimen adherence
Worn at least 80% of days 71 89.9 NA NA
Worn 100% of days 64 81 NA NA
Duet adherence during sex
Worn at least 80% of sex acts 74 93.7 77 93.9
Worn 100% of sex acts 70 88.6 73 89
Ever used Duet precoitally during continuous regimen 1 1.3 1 1.3
Duet ever came out on its own 2 2.5 0 0
Mean/median number of times Duet came out on its own* 1.5 1.5 0 0
Reasons for non-adherence
Main reason Duet not used during sex
Used the Duet every time for sex 69 87.3 74 90.2
Partner refused to use it 4 5.1 3 3.7
Did not have Duet with her/forgot to use it 1 report each 2.6 2 reports each 4.8
Discomfort/having menses/did not have time to insert 1 report each 3.9 0 0
Other 2 2.5 1 1.2
Main reason Duet not used every day
Used the Duet every day 62 78.5 NA NA
Did not have the Duet with her 5 6.3 NA NA
Partner refused to use it 3 3.8 NA NA
Discomfort/did not have sex/having menses/other 2 reports each 10.0 NA NA
Forgot to use it 1 1.3 NA NA
Condom adherence
Worn at least 80% of sex acts 52 65.8 53 65.4
Worn 100% of sex acts 50 63.3 53 65.4
*Denominators and proportions exclude missing data for n = 4 for continuous-use adherence and n = 1 for precoital-use adherence.
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coital group was positive at both follow-up visits).
Emotional problems and social harms
A minority of individuals also reported emotional pro-
blems caused by the Duet: during the continuous regi-
men, four women (5%) reported “fear”, one reported
verbal abuse from the partner, and one reported partner
complaints about the gel. During the precoital regimen,
four women reported “fear”, two cited verbal abuse from
partners, and one reported “shame”.
Discussion
This is the first study to assess acceptability and safety
of the Duet used with a vaginal gel for 14 days continu-
ously or precoitally in an African setting. Although Buf-
ferGel alone and the diaphragm used with an inactive
lubricant have not been shown to be effective in pre-
venting HIV in this setting [12,15], the combined effec-
tiveness of a cervical barrier, such as the Duet and an
effective microbicide, has not yet been tested. Thus, the
safety and acceptability results reported here may inform
Table 3 Acceptability of the Duet among intervention group participants (n = 83)
#%
Very comfortable wearing the Duet continuously 69 86.3
Somewhat comfortable 10 12.5
Not at all 1 92.8
Very comfortable inserting and removing the Duet before and after each act of sex 77 92.8
Somewhat comfortable 5 6.0
Not at all 1 1.2
Definitely would use Duet if I thought I was at risk for HIV and Duet could protect me 68 85.0
I maybe would use the Duet 11 13.8
I maybe would not use the Duet 1 1.3
I definitely would not use the Duet 0 -
Very comfortable opening the gel sachet 79 98.8
Somewhat comfortable 1 1.3
Not at all 00
Very comfortable loading the gel into the Duet 97.5 80
Somewhat comfortable 2.5 2
Not at all
Preferred regimen
Continuous 31 38.8
Precoital 41 51.3
Same 8 10.0
Preferred regimen of partner
Continuous 30 37.5
Precoital 41 51.3
Same 9 11.3
Most favourable characteristic of Duet for participant (top 3)
Duet does not interfere with normal/natural sex 44 55.0
The Duet is reusable 15 18.8
You can put the Duet in yourself 9 11.3
Least favourable characteristic of Duet for participant (top 3)
The Duet might come out during sex 57 71.3
Duet might change the feeling of sex for you 11 13.8
Duet might change the feeling of sex for him 10 12.5
Characteristic participant perceived as most favourable for partner (top 3)
Duet does not interfere with normal/natural sex 56 68.8
The Duet is reusable 10 12.5
You can put the Duet in yourself 10 12.5
Characteristic participant perceived as least favourable for partner (top 3)
The Duet might come out during sex 36 70.0
Duet might change the feeling of sex for him 13 16.3
He might feel Duet in your body during sex 5 6.3
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Page 8 of 13future trials of products such as these, used indepen-
dently or in combination.
Overall, women were very comfortable wearing the
Duet continuously or inserting it precoitally, and the
majority indicated that they would use it in the future if
it were shown to be effective in preventing HIV and
they perceived themselves to be at risk. Since the Duet
and gel were used together, it is difficult to disentangle
attitudes towards the devicea l o n ev e r s u st h eg e la l o n e .
For example, when responding to questions about “Duet
use”, women may have automatically incorporated “gel
use” in their assessment, or may have been referencing
only the device. The majority of women reported being
“very comfortable” with the functional aspects (opening
and loading) of the single-use gel sachets, and thus, it is
likely reasonable to assume that favourable attitudes
towards the Duet applied to impressions of both the
cervical barrier and the gel application process, if not
also the gel itself.
Women who were former MIRA participants and had
previous diaphragm experience (used precoitally) appear
t oh a v eap r e f e r e n c ef o rp r e c o i t a l - u s er e g i m e nf o rt h e
Duet, although the difference was not statistically signifi-
cant at the p < 0.05 level. Further analysis is planned to
more specifically examine the characteristics of women
who favoured continuous versus precoital use. Mirroring
the preferences for one regimen over another, women
w h ow e r ed i a p h r a g me x p e r i e n c e dw e r em o r ec o n s i s t e n t
users of the Duet when asked to use it precoitally,
although again, the difference was not statistically signif-
icant. This study may have been underpowered to detect
significantly reduced uptake of continuous use of this
similar prevention technology because of previous famil-
iarity with precoital insertion. However, because so few
Table 4 Adherence and acceptability of the Duet, by previous diaphragm experience (n = 83)
Dia-naïve ppts
(n = 41)
Dia-experienced ppts
(n = 42)
p value*
Continuous regimen adherence n % n %
Duet regimen adherence
Worn at least 80% of days 37 94.9 34 85.0 0.26
Worn 100% of days 33 84.6 31 77.5 0.57
Duet adherence during sex
Worn at least 80% of sex acts 38 97.4 36 90.0 0.36
Worn 100% of sex acts 36 92.3 34 85.0 0.48
Precoital regimen adherence
Duet adherence during sex
Worn at least 80% of sex acts 36 87.8 41 100.0 0.06
Worn 100% of sex acts 35 85.4 38 92.7 0.48
Acceptability
Very comfortable wearing the Duet continuously 34 85.0 35 87.5 0.74
Somewhat comfortable 6 15.0 4 10.0
Not at all 0 - 1 2.5
Very comfortable inserting and removing the Duet before and after each act of sex 37 90.2 40 95.2 0.51
Somewhat comfortable 3 7.3 2 4.8
Not at all 1 2.4 0 -
Willingness to use Duet if you thought you were at risk for HIV and Duet could protect you 1.00
I definitely would use the Duet 34 85.0 34 85.0
I maybe would use the Duet 5 12.5 6 15.0
I maybe would not use the Duet 1 2.5 0 -
I definitely would not use the Duet 0 - 0 -
Preferred regimen 0.13
Continuous 20 50.0 11 27.5
Precoital 17 42.5 24 60.0
Same 3 7.5 5 12.5
Preferred regimen of partner 0.34
Continuous 18 45.0 12 30.0
Precoital 19 47.5 22 55.0
Same 3 7.5 6 15.0
*P value for the comparison between diaphragm-naïve and diaphragm-experienced participants, based on Fisher’s exact test
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Page 9 of 13women in the region have been exposed to these tech-
nologies, this should not pose a substantial barrier to
future efforts to promote or introduce continuous use of
a female-initiated HIV prevention method. While it is
promising that more than 80% of women overall were
reportedly willing and able to use the Duet continuously
during their 14-day use period, in this study the propor-
tion of sex acts with a Duet in situ was almost identical
for each use regimen. Thus, assignment to continuous
use did not result in higher adherence during sex, when
exposure to HIV or STIs may occur.
One of the previously described Madagascar pilot stu-
dies recently reported that continuous diaphragm use
was associated with four times higher odds of adherent
diaphragm use during sex [20]. However, these findings
were based on a subgroup analysis of participants who
were classified as “continuous users” using an imputed
composite variable created through qualitative and
quantitative data triangulation. Also, the study popula-
tion had at least four monthly sexual partners, com-
pared with our monogamous, married population [20].
In contrast, we examined Duet adherence during sex,
using an intent-to-treat approach based on group
assignment. Of note, among the subgroup of women (n
= 64) who reported full adherence during the continu-
ous use regimen, 97% of sex acts were protected by
Duet (as compared with 89% overall). It is unknown
how promotion of continuous use and its effect on
adherence would change (in either direction) with
longer study duration or with a larger sample size that
would provide greater power to detect differences by
group.
More than half the participants felt that the most
favoured characteristic of the Duet is that it does not
interfere with “normal/natural” sex, indicating that using
the Duet during sex did not change the feeling of sex,
an often cited complaint about male condoms [21,22].
Perceptions of the potential for diminishing sexual plea-
sure for either the participant or her partner were like-
wise important fears to participants, as were concerns
that the device might come out during sex or that the
partner may touch the device with his penis, presumably
because these instances would interrupt the sex act or
sexual pleasure. Sexual pleasure has been discussed as a
critical consideration in microbicide and cervical barrier
acceptability research because the introduction of a gel
could alter the “natural” feeling of sex. Women may
find that a gel increases their pleasure or reduces their
pain, although they may be concerned that partners will
find the lubrication to be unfavourable [23-25].
Women’s top three reasons for liking or disliking the
Duet were virtually identical to their perceptions of
Table 5 Total number of women experiencing adverse events (n), number of AEs (#), and number of AEs per 100
person weeks, by regimen
Continuous regimen
(n = 80)*
Precoital regimen
(n = 83)*
Observation
(n = 20)*
n # #/100 woman
weeks
p
1 N # #/100 woman
weeks
p
2 n # #/100 woman
weeks
Total 28 38 23.8 0.60 32 39 23.5 1.00 11 13 16.3
Reproductive tract (RT) or urinary tract (UT)
related
12 15 9.4 0.42 8 10 6.0 1.00 4 4 5.0
Severity
Mild 20 23 14.4 0.86 22 27 16.3 0.62 10 11 13.8
RT/UT related 5 6 3.8 0.75 7 8 4.8 1.00 3 3 3.8
Moderate 11 15 9.4 1.00 10 12 7.2 0.23 2 2 2.5
RT/UT related 7 9 5.6 0.07 1 2 1.2 1.00 1 1 1.3
Severe 00 - - 00 - - 00 -
RT/UT related 0 0 - - 00 - - 00 -
Relatedness to study products
Definitely 0 0 - - 00 - - -0 -
Probably 4 4 2.5 0.73 6 6 3.6 - -0 -
Possibly 6 9 5.6 0.75 4 4 2.4 - -0 -
Probably not 4 4 2.5 1.00 4 4 2.4 - -0 -
Not related 14 21 13.1 0.21 21 25 15.1 - -1 3 -
* Duet use participants were followed for up to 14 days per regimen. Observation group participants were followed for up to 28 days.
1 P value for the comparison of the proportion of intervention group women reporting an event during the continuous vs. precoital regimen periods (McNemar’s
test)
2 P value for the comparison of the proportion of women reporting an event between those in an intervention group vs. observational controls (Fisher’s exact
test)
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rately assess men’s and women’s perspectives, a growing
body of literature, including data from the MIRA study,
supports the interpretation that the male partners’
acceptability of the Duet may have influenced women’s
own acceptability and use of the device [25-28]. Further
analysis of the study’s qualitative interviews with men
and women will explore these issues in greater depth.
In this study, the Duet appeared safe, when used both
continuously and precoitally, for 14 days. This study
relied on clinical observation and self-report of adverse
events and did not include colposcopic examinations.
The nature and quantity of events observed is what was
expected for a study of this size and duration in this set-
ting. Although not statistically significant, more events
were observed in the intervention groups, and more
gynecological events were classified as “moderate” in the
continuous-use regimen, but this may be attributed to
women’s heightened awareness and more frequent con-
tact with their genitalia when using a product daily
(compared to non-use), and when using a product con-
tinuously as compared with just during sex.
In the North American-based Duet study, the Duet
was also concluded to be safe, although the authors
recommended ongoing monitoring of abdominal and
genital pain in future studies, and attention to peeling
or disruption of the cervical epithelium [14]. In this
study, no epithelial disruptions were observed on specu-
lum exam, although one participant experienced persis-
tent cervical erythema and was discontinued at her first
follow-up visit. Several participants initially reported
pain or discomfort upon inserting, removing and wear-
ing the Duet. Although the majority of these problems
resolved with counselling on proper placement or prac-
tice, these issues should continue to be monitored in
future studies.
In the MIRA study, participants’ reports of problems
associated with diaphragm use decreased substantially
after the first one or two follow-up visits with improving
skills and counselling from clinic staff [29]. Unlike the
contraceptive diaphragm, the Duet is a single-size device
designed for use without medical fitting. Our results
confirm and extend those of Ballagh et al in indicating
that the Duet provides an appropriate fit for most
women, and thus may be appropriate for over-the-coun-
ter use [14].
This study has several strengths and limitations. First,
we aimed to assess the acceptability and safety of two
Duet-use regimens, and both preferences and biological
susceptibility to reproductive tract-or urinary tract-
related AEs may have been biased by the participant’s
first regimen assignment and/or previous exposure to
cervical barriers. The study’s randomized, crossover
design controlled for any possible bias towards the
regimen assigned first or second. We purposively
selected an equal number of women with and without
previous diaphragm experience, and stratified our adher-
ence and acceptability results by this characteristic (few
women reported recent diaphragm use at baseline, so
this was not done for the safety results).
T h i ss t u d yw a ss h o r ti nd u r a t i o n ,a n di ti sd i f f i c u l tt o
predict how acceptability and safety outcomes might
change with longer use time. In this analysis we
included only quantitative, pre-designated measures of
product acceptability, rather than our qualitatively cap-
tured data. This approach potentially limits a broader
understanding of product acceptability, and important
reasons for liking/disliking Duet may have been
overlooked.
Acceptability, adherence and safety measures, with the
exception of clinical observation of AEs, relied on self-
report, which may have been subject to social desirabil-
ity and recall bias. We minimized this bias by measuring
adherence and acceptability in several ways, and found
high concordance between multiple measures (i.e., pro-
portion of acts/days covered and the opt-in selection of
“Not applicable, I used it every time” when asked about
non-use).
Further, participants were not excluded for non-adher-
ence or for disliking the products, and most AEs that
might have warranted discontinuation would have been
observed during pelvic exams. Nonetheless, the level of
condom use reported in this sample of married women
on effective contraception was high, although similar to
other research in this setting [15,30,12], and it is
unknown whether this is from social desirability bias or
from the successful implementation of intensive condom
counselling in this study, and/or previous research stu-
dies. Related to this final point, it is also important to
acknowledge that the women able and willing to join
this study, and meeting entry criteria, may not have
been representative of the general population, nor of
those at highest risk of HIV/STI acquisition.
Conclusions
We found that the Duet was highly acceptable and safe
for use both continuously and precoitally in this African
setting when used for 14-day periods. Further research
should explore the safety of the device with alternative
microbicide candidates as a low-cost, reusable delivery
mechanism and potential disease prevention option. In
this study, assignment to continuous-use regimen did
not equate with more protected sex acts. However, the
s t r a t e g ym a yb em o r ee f f e c t i v ei ne n a b l i n ga d h e r e n c e
over periods of time longer than 14 days. Users familiar
with precoital insertion of cervical barriers or other
methods might require more counselling to encourage
continuous use.
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